全球血液製品市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計血液製品市場將從 2025 年的 385 億美元成長到 2034 年的 799.7 億美元，2026 年至 2034 年的複合年成長率為 8.46%。

受輸血需求不斷成長以及需要使用血液製品的慢性疾病患病率上升的推動，血液製品市場正經歷強勁成長。隨著全球醫療系統致力於改善患者預後，安全有效的血液製品的重要性不言而喻。這個市場涵蓋多種產品，包括全血、紅血球、血漿和血小板，所有這些產品在醫療和外科手術中都發揮著至關重要的作用。人口老化和創傷病例的急劇增加進一步推動了對血液製品的需求，凸顯了高效血液收集、處理和配送系統的必要性。

技術進步正顯著提升血液製品市場的競爭力，血液處理和儲存技術的創新提高了產品的安全性和有效性。自動化採血系統和先進檢測方法的進步提高了營運效率，降低了污染風險。此外，數據分析和人工智慧技術在血液管理系統中的應用最佳化了庫存管理，確保血液製品在最需要的時間和地點都能及時供應。隨著市場的不斷發展，那些優先投資於最尖端科技和品質保證的企業有望獲得競爭優勢。

此外，血液製品市場日益受到旨在確保血液供應安全的法規結構和公共衛生措施的影響。各國政府和衛生組織已實施嚴格的法規，以促進血液安全並鼓勵自願捐血宣傳活動。這種對安全性和可近性的重視正在推動對捐血基礎設施和宣傳項目的投資，從而為市場成長創造機會。隨著對血液製品需求的持續成長，那些遵守監管標準並與當地社區積極互動的公司將在這個重要領域佔據有利地位，取得成功。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 繪製滲透率和成長前景圖
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 市場問題
• 波特五力分析
• PESTLE分析

4. 全球血液製品市場（按類型分類）

• 市場分析、洞察與預測
• 白蛋白
• 免疫球蛋白
• 凝血因子
• 其他

5. 全球血液製品市場依應用領域分類

• 市場分析、洞察與預測
• 出血傷口
• 免疫力缺乏
• HBV
• 破傷風
• 狂犬病
• 血友病
• 其他

6. 全球血液製品市場（依地區分類）

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商格局（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • CSL
  • BPL
  • Mitsubishi Tanabe Pharma Corporation
  • Takeda
  • Octapharma AG
  • Baxter
  • Grifols
  • Kedrion SpA
  • Hualan Bio

The Blood Products Market size is expected to reach USD 79.97 Billion in 2034 from USD 38.50 Billion (2025) growing at a CAGR of 8.46% during 2026-2034.

The Blood Products market is experiencing robust growth, driven by the increasing demand for blood transfusions and the rising prevalence of chronic diseases that necessitate blood product utilization. As healthcare systems worldwide strive to improve patient outcomes, the importance of safe and effective blood products cannot be overstated. This market encompasses a wide range of products, including whole blood, red blood cells, plasma, and platelets, all of which play critical roles in medical treatments and surgical procedures. The growing aging population and the surge in trauma cases are further propelling the demand for blood products, highlighting the need for efficient blood collection, processing, and distribution systems.

Technological advancements are significantly enhancing the capabilities of the Blood Products market, with innovations in blood processing and storage techniques improving product safety and efficacy. The development of automated blood collection systems and advanced testing methods is streamlining operations and reducing the risk of contamination. Additionally, the integration of data analytics and artificial intelligence in blood management systems is optimizing inventory control and ensuring that blood products are available when and where they are needed most. As the market continues to evolve, companies that invest in cutting-edge technologies and prioritize quality assurance will likely gain a competitive advantage.

Moreover, the Blood Products market is increasingly influenced by regulatory frameworks and public health initiatives aimed at ensuring the safety and availability of blood supplies. Governments and health organizations are implementing stringent regulations to enhance blood safety and promote voluntary blood donation campaigns. This focus on safety and accessibility is driving investment in blood donation infrastructure and awareness programs, creating opportunities for growth in the market. As the demand for blood products continues to rise, companies that align their operations with regulatory standards and engage in community outreach will be well-positioned to succeed in this vital sector.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Albumin
• Immunoglobulin
• Clotting Factor
• Others

By Application

• Bleeding Wound
• Immunodeficiency
• HBV
• Tetanus
• Rabies
• Hemophilia
• Others

COMPANIES PROFILED

• CSL, BPL, Mitsubishi Tanabe Pharma Corporation, Takeda, Octapharma AG, Baxter, Grifols, Kedrion SpA, Hualan Bio

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BLOOD PRODUCTS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Albumin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunoglobulin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Clotting Factor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BLOOD PRODUCTS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Bleeding Wound Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Immunodeficiency Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. HBV Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Tetanus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Rabies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Hemophilia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BLOOD PRODUCTS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Type
  • 6.2.2 By Application
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Type
  • 6.3.2 By Application
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Type
  • 6.4.2 By Application
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Type
  • 6.5.2 By Application
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Type
  • 6.6.2 By Application
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL BLOOD PRODUCTS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 CSL
  • 8.2.2 BPL
  • 8.2.3 Mitsubishi Tanabe Pharma Corporation
  • 8.2.4 Takeda
  • 8.2.5 Octapharma AG
  • 8.2.6 Baxter
  • 8.2.7 Grifols
  • 8.2.8 Kedrion SpA
  • 8.2.9 Hualan Bio